Comments: Growth in the quarter was driven by Mounjaro, with sales up 60% to $3.5 billion, and Zepbound, with sales of $1.9 billion. New Products revenue, which consists of Ebglyss, Jaypirca, Kisunla, ...

Ozempic Approval Expanded to Include T2D Patients With Chronic Kidney Disease Omvoh (mirikizumab-mrkz) Humanized immunoglobulin G4 monoclonal antibody that selectively binds to the p19 subunit of ...

Pipeline progress included the approval of Zepbound in the U.S. for moderate-to-severe obstructive sleep apnea in adults with obesity and the approval of Omvoh in the U.S. for moderately to ...

With several key drug approvals, including Zepbound for sleep apnea and Omvoh for Crohn's disease, Eli Lilly continues to innovate and expand its footprint in critical therapeutic areas. Entering 2025 ...

The company adds that the midpoint represents approximately 32% growth compared to 2024, driven by new Lilly medicines such as Zepbound, Mounjaro, Jaypirca, Ebglyss, Omvoh and Kisunla; approvals ...

1 Lilly defines new products as select products launched since 2022, which currently consist of Ebglyss, Jaypirca, Kisunla, Mounjaro, Omvoh and Zepbound. 2 Lilly defines Growth Products as ...

For FY2025, the company anticipates revenue to be in the range of $58 to $61 billion, driven by products such as Jaypirca, Ebglyss, Omvoh, and Kisunla, along with the market expansion of Mounjaro.

in adults with obesity and FDA approval for Omvoh for the treatment of moderately to severely active Crohn’s disease in adults. The company also noted its pending $2.5 billion acquisition of ...

The firm is updating its model after the company’s FY24 results and FY25 guidance as the company management anticipates ongoing topline growth from Jaypirca, Ebglyss, Omvoh and Kisunla and ...